Pharmacotherapy of anemia in cancer patients

Expert Review of Clinical Pharmacology

Volumn 1, Issue 2, 2008, Pages 307-317

  Littlewood, Tim J ^a   Collins, G P ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Cancer anemia; Chemotherapy anemia; Erythropoietin; Quality of life; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CYCLOSPORIN; ERYTHROPOIETIN; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERROUS SULFATE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; IRON; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PLATINUM; RECOMBINANT ERYTHROPOIETIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; EXERCISE TOLERANCE; FATIGUE; FLU LIKE SYNDROME; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN DETERMINATION; HUMAN; HYPERKALEMIA; HYPERTENSION; IRON DEFICIENCY; MYELODYSPLASIA; NEOPLASM; NONHUMAN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PURE RED CELL ANEMIA; QUALITY OF LIFE; REVIEW; SEIZURE; SOLID TUMOR; THROMBOCYTOSIS; VEIN THROMBOSIS;

EID: 49249135437     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.2.307     Document Type: Review

References (71)

1. Drueke TB, Locatelli F, Clyne N et al. Normalisation of haemoglobin level in patients with chronic kidney disease and anaemia. N. Engl. J. Med. 355, 2071-2084 (2006).
2. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin α in chronic kidney disease. N. Engl. J. Med. 355, 2085-2098 (2006).
3. Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer 40, 2293-2306 (2004).
4. Means RT. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells 13, 32-37 (1995).
5. Vogelzang NJ, Breitbart W, Cella D et al. Patient, caregiver and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin. Hematol. 34(Suppl. 2), 4-12 (1997).
6. Law ML, Cai GY, Lin FK et al. Chromosomal assignment of the human erythropoietin gene and its DNA polymorphism. Proc. Natl Acad. Sci. USA 83, 6920-6924 (1986).
7. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur. J. Haematol. 78, 183-205 (2007).
8. Ratcliffe PJ. From erythropoietin to oxygen: hypoxia-inducible factor hydroxylases and the hypoxia signal pathway. Blood Purif. 20, 445-450 (2002).
9. Lacombe C, Mayeux P. Biology of erythropoietin. Haematologica 83, 724-732 (1998).
10. Macdougal IC, Padhi D, Jang G. Pharmacology of darbepoetin α. Nephrol. Dial. Transplant. 22(Suppl. 4), iv2-iv9 (2007).
11. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 283, 990-993 (1999).
12. Cheung JY, Miller BA. Molecular mechanisms of erythropoietin signaling. Nephron 87, 215-222 (2001).
13. Silva M, Benito A, Sanz C et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J. Biol. Chem. 274, 22165-22169 (1999).
14. Walrafen P, Verdier F, Kadri Z et al. Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 105, 600-608 (2005).
15. Wickrema A, Krantz SB, Winkelmann JC, Bondurant MC. Differentiation and erythropoietin receptor gene expression in human erythroid progenitor cells. Blood 80, 1940-1949 (1992).
16. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9(Suppl. 5), 18-30 (2004).
17. Brines ML, Ghezzi P, Keenan S et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl Acad. Sci. USA 97, 10526-10531 (2000).
18. Bath P, Sprigg N. Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke. Cochrane Database Syst. Rev. 18(2), CD005207 (2007).
19. Ludwig H, Fritz E, Kotzmann H et al. Erythropoietin treatment of anemia associated with multiple myeloma. N. Engl. J. Med. 322, 1693-1699 (1990).
20. Abels R. Erythropoietin for anaemia in cancer patients. Eur. J. Cancer 29A(Suppl. 2), S2-S8 (1993).
21. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Once-weekly epoetin β is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br. J. Haematol. 122, 386-393 (2003).
22. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin a on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 19, 2865-2874 (2001).
23. Hedenus M, Adriansson M, San Miguel J et al. Efficacy and safety of darbepoetin α in anaemic patients with lymphoproliferative malignancies; a randomised, double-blind, placebo controlled study. Br. J. Haematol. 122, 394-403 (2003).
24. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin α on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J. Clin. Oncol. 15, 1218-1234 (1997).
25. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin α is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J. Clin. Oncol. 16, 3412-3425 (1998).
26. Reinhardt U, Tulusan A, Angermund R, Lutz H. Increased hemoglobin levels and improved quality-of-life assessments during epoetin α treatment in anemic cancer patients: results of a prospective, multicenter German trial. Oncologist 10, 225-237 (2005).
27. Crawfbrd J, Cella D, Cleeland CS et al. Relationship between changes in haemoglobin level and quality of life during chemotherapy in anaemic patients receiving epoetin α therapy. Cancer 95, 888-895 (2002).
28. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin α in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J. Clin. Oncol. 19, 2875-2882 (2001).
29. Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin CC maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J. Clin. Oncol. 23, 2597-2605 (2005).
30. Witzig TE, Silberstein PT, Loprinzi CL et al. Phase III, randomised, double-blind study of epoetin a compared with placebo in anaemic patients receiving chemotherapy. J. Clin. Oncol. 23, 2069-2074 (2005).
31. Vansteenkiste JF. Every 3 weeks dosing with darbepoetin α: a new paradigm in anaemia management. Cancer Treat. Rev. 32(Suppl. 2), S11-S15 (2006).
32. Fallowfield L, Gagnon D, Zagari M et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin α in patients receiving non-platinum chemotherapy. Br. J. Cancer 87, 1341-1353 (2002).
33. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int. (Suppl. 69), S61-S66 (1999).
34. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. 22, 1301-1307 (2004).
35. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin α versus Oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12, 231-242 (2007).
36. Hedenus M, Birgegard G, Nasman P et al. Addition of intravenous iron to epoetin β increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomised multicenter study. Leukemia 21, 627-632 (2007).
37. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 369, 1502-1504 (2007).
38. Stasi R, Amadori S, Littlewood TJ, Terzoli E, Newland A, Provan AD. Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns. Oncologist 10, 539-554 (2005).
39. Littlewood TJ, Zagari M, Pallister C, Perkins A. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist 8, 99-107 (2003).
40. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br. J. Haematol. 89, 67-71 (1995).
41. Terpos E, Mougiou A, Kouraklis A et al. Prolonged administration of erythropoietin increases erythroid response rate in myclodysplastic syndromes: a Phase II trial in 281 patients. Br. J. Haematol. 118, 174-180 (2002).
42. Spiriti M, Latagliata R, Niscola P et al. Impact of a new dosing regimen of epoetin α on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann. Hematol 84, 167-176 (2005).
43. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 106, 803-811 (2005).
44. Hellstrom-Lindberg E, Negrin R, Stein R et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br. J. Haematol. 99, 344-351 (1997).
45. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of fife. Br. J. Haematol. 120, 1037-1046 (2003).
46. Link H, Boogaerts MA, Fauser AA et al. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 84, 3327-3335 (1994).
47. Martino M, Oliva E, Console G et al. Administration of recombinant human erythropoietin α before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients. Support Care Cancer 13, 182-187 (2005).
48. Baron F, Frere P, Fillet G, Beguin Y. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment. Clin. Cancer Res. 9, 5566-5572 (2003).
49. Vanstraelen G, Baron F, Frere P, Hafraoui K, Filler G, Beguin Y. Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation. Haematologica 90, 1269-1270 (2005).
50. Biggs JC, Atkinson KA, Booker V et al. Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group. Bone Marrow Transplant. 15, 129-134 (1997).
51. Ivanov V, Faucher C, Mohty M et al. Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation. Bone Marrow Transplant. 36, 901-906 (2005)
52. Baron F, Frere P, Beguin Y. Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation when started soon after engraftment. Haematologica 88, 718-720 (2003)
53. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer a systemic, quantitative review. Cancer 91, 2214-2221 (2001).
54. Osterborg A, Brandberg Y, Hedenus M. Impact of epoetin-β on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br. J. Haematol. 129, 206-209 (2005).
55. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J. Natl Cancer Inst. 98, 708-714 (2006).
56. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin α in mainly nonanemic patients with metastatic breast cancer receiving first,line chemotherapy. a survival study. J. Clin. Oncol. 23, 5960-5972 (2005).
57. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362, 1255-1260(200)
58. Wright JR, Ung YC, Julian JA et al. Randomised, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J. Clin. Oncol. 25, 1027-1032 (2007).
59. Lappin TR, Maxwell AP, Johnston PG. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia. Oncologist 12, 362-365 (2007).
60. Steinbrook R. Erythropoietin, the FDA and Oncology. N. Engl. J. Med.356, 2448-2451(2007).
61. Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin. Oncol. 28(2 Suppl. 8), 49-53 (2001).
62. Henke M, Mattern D, Pepe M et aLl. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J. Clin. Oncol. 24,4708-4713 (2006).
63. Ragione FD, Cucciolla V, Borriello A, Oliva A. Erythropoietin receptors on cancer cells: a still open question. J. Clin. Oncol. 25, 1812 (2007).
64. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346,469-475 (2002).
65. Bennett CL, Luminari S, Nissenson AR et al. Pure red-cell aplasia and epoetin therapy. N. Engl. J. Med. 351, 1403-1408 (2004).
66. Locatelli F, Aljama P, Barany P et al. Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here? Nephrol. Dial. Transplant. 19, 288-283 (2004).
67. Quint L, Casadevall N, Giraudier S. Pure red cell aplasia in patients with refractory anaemia treated with two different recombinant erythropoietins. Br. J. Haematol. 124, 842 (2004).
68. Wilson J, Yao GL, Raftery J et al. A systematic review and economic evaluation of epoetin α, epoetin β and darbepoetin α in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol. Assess. 11, 1-220 (2007).
69. Pealer LN, Marfin AA, Petersen LR et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N. Engl. J. Med. 349, 1236-1245 (2003).
70. Ratcliffe P. HIF-1 and HIF-2: working alone or together in hypoxia? J. Clin. Invest. 117, 862-865 (2007).
71. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur. J. Cancer 43, 258-270 (2007).